← Leaderboards
Wendy Jane Fantl
Stanford University
$1,206,971
Attributed
$2,413,942
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $509.2K · FY2014–20$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$2,413,942 · 2
By mechanism
R01$2,036,644 · 1
R21$377,298 · 1
Top collaborators
- Branimir I Sikic4 shared
- John Thomas Leppert2 shared
Most similar at Stanford University
Same institution · by research overlap
- Robert Michael Angelo$7,860,542
- Anshul Kundaje$16,927,829
- Manuel A Rivas$2,174,080
- Stephen Montgomery$23,593,399
- Sandip Biswal$4,838,613
Others in their field
Top investigators on “Biological Markers”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,644,754
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$297,689,086
- Lawrence Corey · Fred Hutchinson Cancer Center$297,689,086
- David R. Weir · University Of Michigan At Ann Arbor$286,732,935
- Jeffrey P Krischer · University Of South Florida$271,114,178
- David Heimbrook · Leidos Biomedical Research, Inc.$227,381,786
Research focus
Biological MarkersChemotherapyResponseInflammatoryComputerized ToolsImmuneCytometryMalignant NeoplasmsSignal PathwayCellsBaseClinical TrialsTargeted TreatmentAntineoplastic AgentsCell TypeCancer CellComplementCell LineCcl2 GeneApoptosisBlood VesselsApoptosis InhibitorCell DeathCell Lineage
Grant awards (6)
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy$171,499
R21 · FY2020 · CA · contact PI
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapy$205,799
R21 · FY2019 · CA · contact PI
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2017 · CA
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2016 · CA
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2015 · CA
(PQD2)New Biomarkers and Pathways to Enhance Cure in Ovarian Cancers$509,161
R01 · FY2014 · CA